Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00290901 · ClinicalTrials.gov registry record · Phase 4
Celebrex vs Tramadol in the Treatment of Chronic Lower Back Pain.
A Phase 4 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 4
- Development phase
- 754
- Enrollment target
NCT00290901 is a Phase 4 study that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 754 participants.
The verdict
NCT00290901, a Phase 4 study, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 754 participants
- Enrollment target
Study Summary
This study investigates if Celebrex is as effective as tramadol hydrochloride (Ultram) for patients with chronic low back pain, when administered over a 6-week period.
Interventions
- DRUG Tramadol Hydrochloride 50mg
- DRUG Celebrex 200mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 754 participants |
| Start Date | 2006-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00290901
The ClinicalTrials.gov registry entry for NCT00290901 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 754 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tramadol Hydrochloride 50mg is the first listed.
NCT00290901 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00290901 about?
NCT00290901 is a clinical study titled "Celebrex vs Tramadol in the Treatment of Chronic Lower Back Pain.". This study investigates if Celebrex is as effective as tramadol hydrochloride (Ultram) for patients with chronic low back pain, when administered over a 6-week period.
What is the current status of trial NCT00290901?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 754 participants. The study started on 2006-03.
What interventions are being tested in trial NCT00290901?
The interventions under investigation include: Tramadol Hydrochloride 50mg (DRUG), Celebrex 200mg (DRUG).
Who is sponsoring clinical trial NCT00290901?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.